Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.48 |
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.45 |
| ▸ | PAM | P19021 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15383902 | 1.00 | NLRP3 (0.48) | NLRP3DGKALPAR1LPAR3ENPP2 | |
| SCHEMBL15383903 | 1.00 | NLRP3 (0.48) | NLRP3DGKALPAR1LPAR3ENPP2 | |
| SCHEMBL17772837 | 1.00 | NLRP3 (0.48) | NLRP3DGKALPAR1LPAR3ENPP2 | |
| SCHEMBL19126951 | 1.00 | NLRP3 (0.48) | NLRP3DGKALPAR1LPAR3ENPP2 | |
| SCHEMBL18955938 | 0.96 | NLRP3 (0.46) | NLRP3DGKALPAR1LPAR3ENPP2 | |
| SCHEMBL18956099 | 0.96 | NLRP3 (0.46) | NLRP3DGKALPAR1LPAR3ENPP2 | |
| SCHEMBL18955964 | 0.96 | NLRP3 (0.46) | NLRP3DGKALPAR1LPAR3ENPP2 | |
| SCHEMBL18955963 | 0.96 | NLRP3 (0.46) | NLRP3DGKALPAR1LPAR3ENPP2 | |
| SCHEMBL18956101 | 0.96 | NLRP3 (0.46) | NLRP3DGKALPAR1LPAR3ENPP2 | |
| SCHEMBL18955937 | 0.96 | NLRP3 (0.46) | NLRP3DGKALPAR1LPAR3ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-7914977-B2 | Transparent support, yellow-, cyan-, and magenta-color-forming photosensitive silver halide emulsion layers, and layer containing coupler; cinematography | FUJIFILM CORPORATION (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7223528-B2 | Photothermographic material and image forming method | FUJIFILM CORPORATION (JP) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | NLRP3 4784/4885DGKA 291/4885LPAR1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.